Downloads: 104

Files in This Item:
File Description SizeFormat 
srep22452.pdf1.52 MBAdobe PDFView/Open
Title: Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma
Authors: Kikuchi, Osamu  kyouindb  KAKEN_id  orcid (unconfirmed)
Ohashi, Shinya  kyouindb  KAKEN_id
Horibe, Tomohisa
Kohno, Masayuki  kyouindb  KAKEN_id
Nakai, Yukie
Miyamoto, Shin'Ichi
Chiba, Tsutomu
Muto, Manabu  kyouindb  KAKEN_id
Kawakami, Koji  kyouindb  KAKEN_id
Author's alias: 大橋, 真也
堀部, 智久
河野, 雅之
宮本, 心一
川上, 浩司
Issue Date: 9-Mar-2016
Publisher: Nature Publishing Group
Journal title: Scientific Reports
Volume: 6
Thesis number: 22452
Abstract: Epidermal growth factor receptor (EGFR) is a key molecule in the pathophysiology of oesophageal squamous cell carcinoma (OSCC). However, EGFR-targeted agents such as anti-EGFR antibody or tyrosine kinase inhibitors for OSCC have not demonstrated any clinical benefits. Recently, a novel chemotherapeutic agent, EGFR(2R)-lytic hybrid peptide, a composite of EGFR-binding peptide and lytic peptide fragments, has been shown to exhibit a potent anti-tumour effect against cancers that express high EGFR levels. In this study, we investigated the validity of employing EGFR(2R)-lytic hybrid peptide against OSCC cells both in vitro and in vivo. Additionally, the toxicity of this peptide was assessed in mice. We found high EGFR expression levels on the cell surface of OSCC cells, and the EGFR-binding peptide fragment showed high affinity for OSCC cells. A potent cytotoxic effect was induced within 30 minutes by the exposure of OSCC cells to EGFR(2R)-lytic hybrid peptide. Furthermore, EGFR(2R)-lytic hybrid peptide markedly suppressed the tumour growth of OSCC cells in a xenograft model. Moreover, it did not cause any identifiable adverse effects in mice. Taken together, EGFR(2R)-lytic hybrid peptide was shown to be a valid therapeutic agent against OSCC, providing a crucial rationale regarding novel EGFR-targeted therapies against OSCC.
Rights: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit
DOI(Published Version): 10.1038/srep22452
PubMed ID: 26956916
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.